RATING
2022-04-15 |
B
|
Neutral
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Sell
|
|
Return On Asset: |
Sell
|
|
DE: |
Neutral
|
|
P/E: |
Strong Sell
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/20 | 4/20 | 1/21 | 2/21 | 3/21 | 4/21 |
Revenue | n/a | | | n/a | n/a | n/a |
Gr.Profit | n/a | | | n/a | n/a | n/a |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -9.86 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-1.68x
|
Company: PE -9.86 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 98.85 - 101.13
( +/- 1.14%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2022-03-11 | Nova Tina Susan | Sell | 17 776 | Common Stock |
2022-03-11 | Nova Tina Susan | Sell | 3 067 | Common Stock |
2022-03-11 | Nova Tina Susan | Sell | 4 800 | Stock Option (right to buy) |
2022-03-11 | Nova Tina Susan | Sell | 15 000 | Stock Option (right to buy) |
2022-03-11 | Nova Tina Susan | Sell | 5 000 | Stock Option (right to buy) |
INSIDER POWER |
0.00
|
Last
100 transactions |
Buy:
416 073 | Sell:
1 553 839 |
Forecast:
01:40 - $104.05
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$99.99 (0.00% )
|
Volume |
0 mill
|
Avg. Vol. |
1.473 mill
|
% of Avg. Vol |
0 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For ARNA
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.